Pelthos Therapeutics Inc. 8-K

What Happened
Pelthos Therapeutics Inc. announced the appointment of John M. Gay (age 49) as Chief Financial Officer, treasurer and secretary, effective April 10, 2026. Mr. Gay joined Pelthos in July 2025 as Senior Vice President, Finance & Accounting and previously held CFO roles at LNHC, Inc. and Novan, Inc., and finance roles at several other companies. The Board terminated Francis Knuettel II as CFO effective April 10, 2026; the company expects to negotiate a separation agreement under his existing employment agreement.

Key Details

• Effective date: April 10, 2026.
• Compensation: annual base salary of $425,000 and eligible for an annual bonus with a 40% target of base salary; bonus paid no later than 75 days after fiscal year end.
• Employment terms: standard termination provisions for cause and good reason; full Employment Agreement filed as Exhibit 10.1 to the 8-K.
• Governance/disclosures: press release announcing the appointment furnished as Exhibit 99.1; company disclosed Mr. Gay has no related‑party arrangements and no family ties to other executives or directors.

Why It Matters
A CFO change is material for investors because the CFO oversees financial reporting, controls and investor communications. The filing confirms Pelthos has promoted an experienced finance executive already on staff, sets clear compensation terms, and indicates a forthcoming separation arrangement for the prior CFO. Investors should note the effective date and review the filed Employment Agreement and company press release for further financial governance details.